168 related articles for article (PubMed ID: 30811287)
21. New hope for young breast cancer patients.
Peres J
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214565
[No Abstract] [Full Text] [Related]
22. Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study.
Dodson A; Zabaglo L; Yeo B; Miller K; Smith I; Dowsett M
J Clin Pathol; 2016 Feb; 69(2):128-35. PubMed ID: 26281860
[TBL] [Abstract][Full Text] [Related]
23. Breast density influences tumor subtypes and tumor aggressiveness.
Kerlikowske K; Phipps AI
J Natl Cancer Inst; 2011 Aug; 103(15):1143-5. PubMed ID: 21795663
[No Abstract] [Full Text] [Related]
24. [Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].
Semilgazov VF; Manikhas AG; Semiglazov VV; Bozhok AA; Dashian GA; Ivanov VG; Paltuev RM; Vasil'ev AG; Shchedrin DE; Ermachenkova AM; Nikitina IV; Pen'kov KD; Bessonov AA; Tabagua TT; Kolar'kova VV
Vopr Onkol; 2011; 57(5):567-77. PubMed ID: 22238925
[No Abstract] [Full Text] [Related]
25. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
[TBL] [Abstract][Full Text] [Related]
26. [Evidence-based radiotherapy in the treatment of early-stage invasive breast cancer: traditional clinical features and biomarkers].
Fodor J
Magy Onkol; 2009 Mar; 53(1):7-14. PubMed ID: 19318321
[TBL] [Abstract][Full Text] [Related]
27. Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?
Paplomata E; Nahta R; O'Regan RM
Cancer; 2015 Feb; 121(4):517-26. PubMed ID: 25346473
[TBL] [Abstract][Full Text] [Related]
28. Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean).
Colleoni M; Rotmensz N; Martinelli G; Gelber R; Coates A; Goldhirsch A
Ann Oncol; 2004 Feb; 15(2):355-6. PubMed ID: 14760134
[No Abstract] [Full Text] [Related]
29. Adjuvant endocrine therapy for premenopausal hormone receptor-positive breast cancer; much done, more to do.
Higgins MJ; Wolf AC
Oncology (Williston Park); 2009 Jan; 23(1):40, 42, 44. PubMed ID: 19283920
[No Abstract] [Full Text] [Related]
30. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
31. More treatment options for women with hormone receptor-positive breast cancer: guideline update, studies lead to advances in care.
Printz C
Cancer; 2014 Oct; 120(19):2939-40. PubMed ID: 25241884
[No Abstract] [Full Text] [Related]
32. Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer?
Mackey JR
J Clin Oncol; 2011 Apr; 29(12):1504-6. PubMed ID: 21422423
[No Abstract] [Full Text] [Related]
33. Clinicopathological features and treatment strategy for triple-negative breast cancer.
Yamamoto Y; Iwase H
Int J Clin Oncol; 2010 Aug; 15(4):341-51. PubMed ID: 20632057
[TBL] [Abstract][Full Text] [Related]
34. Seeds and soil: unraveling the role of local tumor stroma in distant metastasis.
Duda DG; Ancukiewicz M; Isakoff SJ; Krop IE; Jain RK
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25082335
[No Abstract] [Full Text] [Related]
35. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues.
Shimizu C; Fukutomi T; Tsuda H; Akashi-Tanaka S; Watanabe T; Nanasawa T; Sugihara K
J Surg Oncol; 2000 Jan; 73(1):17-20. PubMed ID: 10649273
[TBL] [Abstract][Full Text] [Related]
36. Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.
Bogina G; Lunardi G; Coati F; Zamboni G; Gori S; Bortesi L; Marconi M; Cassandrini PA; Turazza M; Cortesi L; DeMatteis E; Ficarra G; Ibrahim T; Serra P; Medri L; Giraudi S; Lambertini M; Carli F; Foglietta J; Sidoni A; Nunzi M; Ficorella C; Diadema MR; Del Mastro L
Tumori; 2015; 101(4):398-403. PubMed ID: 26045108
[TBL] [Abstract][Full Text] [Related]
37. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
[TBL] [Abstract][Full Text] [Related]
38. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer.
Wangchinda P; Ithimakin S
World J Surg Oncol; 2016 Aug; 14(1):223. PubMed ID: 27557635
[TBL] [Abstract][Full Text] [Related]
39. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
40. The Japanese Breast Cancer Society Clinical Practice Guideline for pathological diagnosis of breast cancer.
Horii R; Honma N; Ogiya A; Kozuka Y; Fukuda T; Yoshida M; Ohsumi S; Mukai H;
Breast Cancer; 2015 Jan; 22(1):59-65. PubMed ID: 25022266
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
